KeraMed

Executive Summary

KeraMed, Inc. is a privately held medical device company dedicated exclusively to developing minimally invasive surgical implants for corneal blindness. Its lead product, the KeraKlear Artificial Cornea, is a foldable, non-penetrating implant designed to treat various forms of corneal disease. Unlike traditional penetrating keratoplasty, which requires donor tissue and carries risks of rejection, KeraKlear offers a synthetic, pre-shaped alternative that can be implanted through a small incision, reducing surgical time and recovery. With over 12 million people worldwide blinded by corneal diseases and a severe shortage of donor corneas, KeraKlear addresses a critical unmet need. The company was founded by a corneal surgeon and is ISO13485:2016 and CE Mark certified, indicating compliance with international quality standards for medical devices.

Upcoming Catalysts (preview)

• Q3 2026FDA Investigational Device Exemption (IDE) approval for US pivotal trial50% success
• Q2 2026Publication of long-term clinical data from European post-market study70% success
• Q4 2026Strategic partnership or funding round for US commercialization40% success